Psychemedics

Psychemedics Financial Leverage

The Financial Leverage (Equity Multiplier) of Psychemedics (PMDI) as of Oct 16, 2026 is 1.62. In the previous year, Financial Leverage (Equity Multiplier) was 1.85 — a change of -12.23% (lower).

Financial Leverage

1.62

YoY

-12.23%

Last updated:

Financial Leverage (Equity Multiplier) of Psychemedics is 2024 1.62 . Financial Leverage (Equity Multiplier) of Psychemedics was 2023 1.85 . It decreases by -12.23% lower compared to the previous year.

The Psychemedics Financial Leverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Leverage
Date
Financial Leverage
Jan 1, 2017
1.42 USD
Jan 1, 2018
1.33 USD
Jan 1, 2019
1.64 USD
Jan 1, 2020
1.92 USD
Jan 1, 2021
1.76 USD
Jan 1, 2022
1.74 USD
Jan 1, 2023
1.85 USD
Jan 1, 2024
1.62 USD
The Psychemedics Financial Leverage history
YEARFinancial LeverageYoY
1.62-12.23%
1.85+6.23%
1.74-1.21%
1.76-8.24%
1.92+17.21%
1.64+22.90%
1.33-6.46%
1.42-11.21%
1.60-15.10%
1.89+0.70%
1.88—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Psychemedics Stock analysis

What does Psychemedics do? Psychemedics Corp, trading under the ticker PMDI, is a U.S.-based company headquartered in Acton, Massachusetts. The company specializes in drug testing services, focusing on the analysis of hair samples to detect the presence of drugs of abuse. With 204 full-time employees, Psychemedics operates within the Health Care sector, specifically in the Health Care industry. The company's primary service involves conducting drug tests and reporting results to clients, including training for sample collection and storage of positive samples for a fee per unit tested. Its testing methodology provides detailed information on the approximate amount of drug ingested and historical data on drug use patterns over time. Psychemedics went public on January 22, 1987, marking the beginning of its journey as a publicly traded entity. The company's website, https://www.psychemedics.com/, serves as a primary source of information for its services and operations. While the company's core business is centered on drug testing, it does not disclose specific product names or additional services beyond the scope of hair sample analysis and reporting. Psychemedics maintains a presence in the U.S. market, with its operations primarily focused on providing reliable and detailed drug testing solutions to its clients. The company's approach to testing emphasizes both the immediate detection of drug use and the ability to track usage patterns over extended periods, offering a comprehensive service for its customers. Psychemedics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Psychemedics stock

Financial Leverage (Equity Multiplier) of Psychemedics is 1.62 in 2024.

Financial Leverage (Equity Multiplier) of Psychemedics changed from 1.85 to 1.62, representing a -12.23% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Financial Leverage (Equity Multiplier) Psychemedics since 2006 – with annual values, charts, and detailed analysis.

Financial leverage, also known as the equity multiplier, measures total assets relative to equity. Higher leverage amplifies both returns and risks.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Leverage (Equity Multiplier)'s Psychemedics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Psychemedics

All Key Metrics — Psychemedics